What is the Kainos Medicine Inc. stock price forecast?

Kainos Medicine Inc. is currently trading at ₩1,087. View real-time AI analysis on Alpha Lenz.

What is Kainos Medicine Inc. insider trading activity?

View the latest insider trading data for Kainos Medicine Inc. on Alpha Lenz.

What is Kainos Medicine Inc.'s P/E ratio?

Kainos Medicine Inc.'s P/E ratio is -2.5.

Kainos Medicine Inc.

KRX · 284620

₩1,087+0(+0.00%)Market closed

Ask about Kainos Medicine Inc.'s future dividend policy...

Alpha Chat Insight

“Kainos Medicine Inc. trades at a P/E of -2.5 (undervalued) with modest ROE of -180.1%.”

Ask for details →

Company Overview

Kainos Medicine Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative drugs. Specializing in small molecule therapies, Kainos Medicine focuses on providing effective treatments for various therapeutic areas, including oncology and neurodegenerative diseases. With an emphasis on groundbreaking scientific approaches, the company leverages its proprietary technologies to discover and develop new medicines aimed at improving patient outcomes and addressing unmet medical needs. In the pharmaceutical industry, Kainos Medicine plays a crucial role in advancing drug development processes and contributing to medical advancements. Its commitment to extensive research and rigorous clinical trials ensures the safety and efficacy of its drug candidates, supporting its position as a valuable player in the global healthcare and pharmaceutical markets.

CEO이기섭

Websitehttps://www.kainosmedicine.com

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2024

Profile

₩35,965,517,911Market Cap

₩590,366,150Revenue

33.09MShares Out

0Employees

Margins

71.46%Gross

-1650.95%EBITDA

-2087.58%Operating

-2064.66%Pre-Tax

-2064.85%Net

Valuation

-2.48P/E

16.93P/B

51.27EV/Sales

-3.18EV/EBITDA

-3.05P/FCF

Growth (CAGR)

-29.18%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-76.84%ROA

-180.07%ROE

-76.54%ROIC

Financial Health

₩3,834,169,270Cash & Cash Equivalents

₩1,033,772,970Net Debt

82.87%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Kainos Medicine Inc. trades at a P/E of -2.5 (undervalued) with modest ROE of -180.1%.”

Ask for details →

Frequently Asked Questions

Kainos Medicine Inc. (ticker: 284620) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $36.0B.

The current price is ₩1,087 with a P/E ratio of -2.48x and P/B of 16.93x.

ROE is -180.07% and operating margin is -2087.58%. Annual revenue is $590M.